IL-17 and related cytokines involved in systemic sclerosis: Perspectives

References

• Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis. 1998;57:682–686.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA. Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437–2444.
   PubMed Web of Science ®Google Scholar
• Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005;26:587–595.
   PubMed Web of Science ®Google Scholar
• O'Reilly S, Hugle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology. 2012;51:1540–1549.
   PubMed Web of Science ®Google Scholar
• Brembilla NC, Chizzolini C. T cell abnormalities in systemic sclerosis with a focus on Th17 cells. Eur Cytokine Netw. 2012;23:128–139.
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123–1132.
   PubMed Web of Science ®Google Scholar
• Weaver CT, Elson CO, Fouser LA, et al. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol. 2013;8:477–512.
   PubMed Web of Science ®Google Scholar
• Lei L, He ZY, Zhao C, et al. Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis. Int J Rheum Dis. 2016;19:392–404.
   PubMed Web of Science ®Google Scholar
• Stockinger B, Veldhoen M, Martin B. Th17 T cells: linking innate and adaptive immunity. Semin Immunol. 2007;19:353–361.
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421:744–748.
   PubMed Web of Science ®Google Scholar
• Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003;198:1951–1957.
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–240.
   PubMed Web of Science ®Google Scholar
• Singh RP, Hasan S, Sharma S, et al. Th17 cells in inflammation and autoimmunity. Autoimmun Rev. 2014;13:1174–1181.
   PubMed Web of Science ®Google Scholar
• Karczewski J, Dobrowolska A, Rychlewska-Hanczewska A, et al. New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis. Autoimmunity. 2016;49:435–450.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy, and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2017 [Nov 1]. doi: 10.1111/bjd.16102
   Web of Science ®Google Scholar
• Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008;9:650–657.
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121–1133.
   PubMed Web of Science ®Google Scholar
• Jin D, Zhang L, Zheng J, et al. The inflammatory Th 17 subset in immunity against self and non-self antigens. Autoimmunity. 2008;41:154–162.
   PubMed Web of Science ®Google Scholar
• Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008;9:641–649.
   PubMed Web of Science ®Google Scholar
• Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10:857–863.
   PubMed Web of Science ®Google Scholar
• Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009;10:864–871.
   PubMed Web of Science ®Google Scholar
• Donnelly RP, Sheikh F, Dickensheets H, et al. Interleukin-26: an IL-10-related cytokine produced by Th17 cells. Cytokine Growth Factor Rev. 2010;21:393–401.
   PubMed Web of Science ®Google Scholar
• Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol. 1995;155:5483–5486.
   PubMed Web of Science ®Google Scholar
• Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556–567.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol. 2002;71:1–8.
   PubMed Web of Science ®Google Scholar
• Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum. 2000;43:2455–2463.
   PubMed Web of Science ®Google Scholar
• Murata M, Fujimoto M, Matsushita T, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci. 2008;50:240–242.
   PubMed Web of Science ®Google Scholar
• Yang X, Yang J, Xing X, et al. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther. 2014;16:R4.
   PubMed Web of Science ®Google Scholar
• Fenoglio D, Battaglia F, Parodi A, et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol. 2011;139:249–257.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, et al. Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int. 2012;32:2653–2660.
   PubMed Web of Science ®Google Scholar
• Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One. 2009;4:e5903.
   PubMed Web of Science ®Google Scholar
• Truchetet ME, Brembilla NC, Montanari E, et al. Interleukin-17A + cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum. 2013;65:1347–1356.
   PubMed Web of Science ®Google Scholar
• Olewicz-Gawlik A, Danczak-Pazdrowska A, Kuznar-Kaminska B, et al. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. Int J Rheum Dis. 2014;17:664–670.
   PubMed Web of Science ®Google Scholar
• Bălănescu P, Lădaru A, Bălănescu E, et al. IL-17, IL-6 and IFN-γ in systemic sclerosis patients . Rom J Intern Med. 2015;53:44–49.
   PubMed Web of Science ®Google Scholar
• Rolla G, Fusaro E, Nicola S, et al. Th-17 cytokines and interstitial lung involvement in systemic sclerosis. J Breath Res. 2016;10:046013.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hou W, Xu K, et al. The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis. Hum Immunol. 2015;76:22–29.
   PubMed Web of Science ®Google Scholar
• Nakashima T, Jinnin M, Yamane K, et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol. 2012;188:3573–3583.
   PubMed Web of Science ®Google Scholar
• Mathian A, Parizot C, Dorgham K, et al. Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis. 2012;71:1227–1234.
   PubMed Web of Science ®Google Scholar
• Gourh P, Arnett FC, Assassi S, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009;11:R147.
   PubMed Web of Science ®Google Scholar
• Brembilla NC, Montanari E, Truchetet ME, et al. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther. 2013;15:R151.
   PubMed Web of Science ®Google Scholar
• Yoshizaki A, Yanaba K, Iwata Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol. 2010;185:2502–2515.
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Hasegawa M, Matsushita T, et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum. 2012;64:3726–3735.
   PubMed Web of Science ®Google Scholar
• Mi S, Li Z, Yang HZ, et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol. 2011;187:3003–3014.
   PubMed Web of Science ®Google Scholar
• Lei L, Zhong XN, He ZY, et al. IL-21 induction of CD4+ T cell differentiation into Th17 cells contributes to bleomycin-induced fibrosis in mice. Cell Biol Int. 2015;39:388–399.
   PubMed Web of Science ®Google Scholar
• Simonian PL, Roark CL, Wehrmann F, et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol. 2009;182:657–665.
   PubMed Web of Science ®Google Scholar
• Gasse P, Riteau N, Vacher R, et al. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS One. 2011;6:e23185.
   PubMed Web of Science ®Google Scholar
• Wilson MS, Madala SK, Ramalingam TR, et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med. 2010;207:535–552.
   PubMed Web of Science ®Google Scholar
• Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8:221–233.
   PubMed Web of Science ®Google Scholar
• Brown M, Postlethwaite AE, Myers LK, et al. Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts. Clin Rheumatol. 2012;31:973–981.
   PubMed Web of Science ®Google Scholar
• Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183:2593–2603.
   PubMed Web of Science ®Google Scholar
• Asano Y, Sato S. Vasculopathy in scleroderma. Semin Immunopathol. 2015;37:489–500.
   PubMed Web of Science ®Google Scholar
• Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum. 2004;50:1721–1733.
   PubMed Web of Science ®Google Scholar
• Liu M, Yang J, Xing X, et al. Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway. Arthritis Res Ther. 2014;16:4223.
   PubMed Web of Science ®Google Scholar
• Liu M, Yang J, Li M. Tanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway. Clin (Sao Paulo). 2015;70:250–256.
   PubMed Web of Science ®Google Scholar
• Fava A, Cimbro R, Wigley FM, et al. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. Arthritis Res Ther. 2016;18:99.
   PubMed Web of Science ®Google Scholar
• Boin F, Rosen A. Autoimmunity in systemic sclerosis: current concepts. Curr Rheumatol Rep. 2007;9:165–172.
   PubMedGoogle Scholar
• Reveille JD, Solomon DH. American College of Rheumatology Ad Hoc Committee of Immunologic Testing G. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49:399–412.
   PubMed Web of Science ®Google Scholar
• Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and research group database. Ann Rheum Dis. 2007;66:754–763.
   PubMed Web of Science ®Google Scholar
• Wurster AL, Rodgers VL, Satoskar AR, et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med. 2002;196:969–977.
   PubMed Web of Science ®Google Scholar
• Wei L, Laurence A, Elias KM, et al. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem. 2007;282:34605–34610.
   PubMed Web of Science ®Google Scholar
• Parrish-Novak J, Foster DC, Holly RD, et al. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol. 2002;72:856–863.
   PubMed Web of Science ®Google Scholar
• Ozaki K, Spolski R, Ettinger R, et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol. 2004;173:5361–5371.
   PubMed Web of Science ®Google Scholar
• Mehta DS, Wurster AL, Grusby MJ. Biology of IL-21 and the IL-21 receptor. Immunol Rev. 2004;202:84–95.
   PubMed Web of Science ®Google Scholar
• Distler JH, Jungel A, Kowal-Bielecka O, et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 2005;52:856–864.
   PubMed Web of Science ®Google Scholar
• Diaz-Gallo LM, Simeon CP, Broen JC, et al. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis. 2013;72:1233–1238.
   PubMedGoogle Scholar
• Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119:2052–2061.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967–974.
   PubMed Web of Science ®Google Scholar
• Maurer B, Distler A, Suliman YA, et al. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis. 2014;73:1880–1887.
   PubMed Web of Science ®Google Scholar
• Frohlich A, Marsland BJ, Sonderegger I, et al. IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood. 2007;109:2023–2031.
   PubMed Web of Science ®Google Scholar
• Castermans K, Tabruyn SP, Zeng R, et al. Angiostatic activity of the antitumor cytokine interleukin-21. Blood. 2008;112:4940–4947.
   PubMed Web of Science ®Google Scholar
• Moroz A, Eppolito C, Li Q, et al. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol. 2004;173:900–909.
   PubMed Web of Science ®Google Scholar
• Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119:3573–3585.
   PubMed Web of Science ®Google Scholar
• Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol. 2011;23:159–163.
   PubMed Web of Science ®Google Scholar
• Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med. 2009;87:523–536.
   PubMed Web of Science ®Google Scholar
• Aden N, Shiwen X, Aden D, et al. Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology. 2008;47:1754–1760.
   PubMed Web of Science ®Google Scholar
• Van Praet JT, Smith V, Haspeslagh M, et al. Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study. Arthritis Res Ther. 2011;13:R35.
   PubMed Web of Science ®Google Scholar
• Brembilla NC, Dufour AM, Alvarez M, et al. IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Ann Rheum Dis. 2016;75:1697–1705.
   PubMed Web of Science ®Google Scholar
• Truchetet ME, Brembilla NC, Montanari E, et al. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther. 2011;13:R166.
   PubMed Web of Science ®Google Scholar
• Hikami K, Ehara Y, Hasegawa M, et al. Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis. Biochem Biophys Res Commun. 2008;373:403–407.
   PubMed Web of Science ®Google Scholar
• Liang M, Wang J, Chu H, et al. Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis. Mediators Inflamm. 2013;2013:209179.
   PubMed Web of Science ®Google Scholar
• Sonnenberg GF, Nair MG, Kirn TJ, et al. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med. 2010;207:1293–1305.
   PubMed Web of Science ®Google Scholar
• Duvallet E, Semerano L, Assier E, et al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med. 2011;43:503–511.
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, et al. receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699–5708.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–725.
   PubMed Web of Science ®Google Scholar
• Rueda B, Broen J, Torres O, et al. The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype. Ann Rheum Dis. 2009;68:253–256.
   PubMed Web of Science ®Google Scholar
• Wines BD, Yap ML, Powell MS, et al. Distinctive expression of Interleukin-23 receptor subunits on human Th17 and gammadelta T cells. Immunol Cell Biol. 2016;95:272–279.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278:1910–1914.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–238.
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441:231–234.
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179–189.
   PubMed Web of Science ®Google Scholar
• Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950–957.
   PubMed Web of Science ®Google Scholar
• Komura K, Fujimoto M, Hasegawa M, et al. Increased serum interleukin 23 in patients with systemic sclerosis. J Rheumatol. 2008;35:120–125.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Gourh P, Shete S, et al. Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis. J Rheumatol. 2009;36:2715–2723.
   PubMed Web of Science ®Google Scholar
• Nakayama W, Jinnin M, Tomizawa Y, et al. Dysregulated interleukin-23 signalling contributes to the increased collagen production in scleroderma fibroblasts via balancing microRNA expression. Rheumatology. 2017;56:145–155.
   PubMed Web of Science ®Google Scholar
• Truchetet ME, Allanore Y, Montanari E, et al. Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis. Ann Rheum Dis. 2012;71:2044–2050.
   PubMed Web of Science ®Google Scholar
• Dantas AT, de Almeida AR, Sampaio M, et al. Corticosteroid inhibits chemokines production in systemic sclerosis patients. Steroids. 2017;127:24–30.
   PubMed Web of Science ®Google Scholar
• Leonardi CL. Antibodies in the treatment of psoriasis: IL-12/23 p40 and IL-17a. Semin Cutan Med Surg. 2016;35:S74–S77.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Leonardi C, Griffiths CE, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012;66:731–741.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000–1006.
   PubMed Web of Science ®Google Scholar
• Menter A, Cather JC, Jarratt M, et al. Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis affecting different body regions: a pooled analysis of four Phase 3 studies. Dermatol Ther (Heidelb). 2016;6:639.
   PubMed Web of Science ®Google Scholar
• Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630–2640.
   PubMed Web of Science ®Google Scholar
• Ichihara A, Jinnin M, Ihn H. Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis. Clin Exp Rheumatol. 2017;35:208–210.
   PubMed Web of Science ®Google Scholar